Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of the Activity of Weekly Paclitaxel, Topotecan Plus Oral Estramustine Phosphate in Metastatic Hormone-Refractory Prostate Carcinoma

NCT00084565 is registered in ClinicalTrials.gov with Fox Chase Cancer Center as lead sponsor.

NCT NCT00084565
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00084565 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of the Activity of Weekly Paclitaxel, Topotecan Plus Oral Estramustine Phosphate in Metastatic Hormone-Refractory Prostate Carcinoma
Lead sponsor
Fox Chase Cancer Center
Phase
Phase 2
Overall status
Withdrawn
Start date
November 30, 2003
Completion date
November 30, 2004
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer